Updated 3/5/25
Amgen Inc. (NASDAQ: AMGN) is one of the largest biotechnology companies in the world, known for its innovative therapies that treat everything from cancer to autoimmune diseases. With a strong reputation in the healthcare industry and a track record of steady revenue growth, Amgen has also become a favorite among dividend investors looking for consistent income.
While the biotech sector isn’t always the first place income-focused investors look, Amgen stands out thanks to its reliable dividend payments and history of growth. It offers a compelling combination of steady cash flow, defensive qualities, and a growing dividend. But is it the right fit for a long-term dividend portfolio? Let’s take a deep dive into Amgen’s dividend profile, financial stability, valuation, and potential risks.
📊 Key Dividend Metrics
💰 Forward Dividend Yield: 3.01%
📈 5-Year Average Dividend Yield: 2.99%
💵 Forward Annual Dividend: $9.52 per share
🚀 5-Year Dividend Growth Rate: ~10%
📆 Next Dividend Payment Date: March 7, 2025
❌ Ex-Dividend Date: May 16, 2025
💸 Payout Ratio: 119.05%
Dividend Overview
Amgen has been a reliable dividend payer since initiating its first payout in 2011. The current dividend yield of just over 3% is competitive within the biotech sector, especially for investors looking for passive income without sacrificing too much growth potential.
Recently, Amgen increased its dividend by 5.8%, which is slightly lower than its historical dividend growth rate of around 10% per year. This may suggest a more conservative approach moving forward, especially considering the company’s elevated payout ratio.
A payout ratio above 100% isn’t necessarily a red flag if the company has strong free cash flow to support the dividend. However, it does indicate that earnings alone aren’t enough to fully cover dividend payments. Amgen’s ability to maintain and grow its dividend will depend on earnings stabilization and continued strong cash flow generation.
Dividend Growth and Safety
Dividend Growth History
Amgen has consistently increased its dividend for 12 years, making it a strong candidate for dividend growth investors. Over the past five years, the company has maintained an average dividend growth rate of about 10%. However, the most recent increase was more modest at 5.8%, signaling a potential shift towards slower, more sustainable growth.
Dividend Safety Considerations
One of the biggest concerns for dividend safety is the payout ratio, which currently sits above 100%. While this isn’t an immediate concern due to the company’s strong cash flow, it does indicate that Amgen is paying out more than it earns in net income.
On the positive side, Amgen generates significant free cash flow, which is crucial for dividend sustainability. With a levered free cash flow of $13.73 billion, the company has more than enough cash to fund its dividend payments despite the high payout ratio. However, earnings growth will need to rebound to maintain long-term sustainability.
Debt is another factor to consider. Amgen carries a significant amount of debt, with a total of $60.88 billion. A high debt burden can sometimes put pressure on dividend payments if the company needs to prioritize debt reduction. As long as free cash flow remains strong, this shouldn’t be a problem in the near term, but it’s something to watch.
Chart Analysis
The price action in Amgen (AMGN) over the past year tells an interesting story of momentum shifts and trend reversals. Looking at the chart, the stock has been through a clear cycle, with a strong rally, a significant correction, and now a promising recovery.
In the earlier part of the chart, the stock experienced a strong uptrend, making higher highs through mid-2024 before losing steam. This was accompanied by the 50-day moving average (orange line) trending well above the 200-day moving average (blue line), a classic bullish signal. However, the stock peaked around the $325 range before entering a prolonged period of weakness.
As AMGN declined, the 50-day moving average eventually crossed below the 200-day moving average—often referred to as a death cross—which signaled a bearish phase. This sell-off bottomed in late 2024, with the stock dipping below $275 before starting its recovery. The drop was accompanied by an increase in trading volume, suggesting that institutional investors were likely involved in the selling.
Now, the price action looks much more constructive. AMGN has bounced back sharply, reclaiming key levels and pushing back above the 50-day moving average. The 200-day moving average, which had been sloping downward, is starting to flatten out, indicating that selling pressure has eased.
The latest five candlesticks show some interesting price behavior. There have been multiple green candles, reflecting sustained buying interest. The wicks on some of these candles suggest that sellers attempted to push prices lower but were met with strong demand. This indicates that bulls are currently in control.
Volume trends also support the recovery. While there was a major spike in volume during the initial decline, the recent rally has been accompanied by steady but moderate volume, suggesting a more sustainable climb rather than a speculative surge.
The RSI (Relative Strength Index) at the bottom of the chart has been rising steadily, currently sitting at elevated levels. This means the stock has regained strength, but it’s worth noting that RSI is approaching overbought territory. If it moves above 70, it could indicate that the stock is due for a short-term pullback before making its next move.
One key level to watch is the previous resistance zone near $325. This area acted as a ceiling before the last big sell-off, so if AMGN continues its climb, it will need to break through this level convincingly. If it fails, there could be another pullback before attempting another push higher.
The moving averages are also at an important juncture. If the 50-day moving average continues moving higher and crosses back above the 200-day, it would trigger a golden cross, a classic bullish reversal signal that could attract more buyers.
Overall, the chart suggests that sentiment around AMGN has improved significantly since the late-2024 sell-off. The stock has rebounded above key moving averages, volume is stabilizing, and momentum indicators are showing strength. However, it will need to clear resistance levels and sustain buying pressure to confirm the next leg higher.
Analyst Ratings
Amgen Inc. (AMGN) has recently seen mixed sentiment from analysts, with both upgrades and downgrades shaping investor expectations. The consensus 12-month price target currently stands at $314.09, indicating a slight upside from its current price.
🔼 Upgrades:
- 📊 Piper Sandler – On February 10, 2025, Piper Sandler reiterated its “Overweight” rating and raised the price target from $310 to $329. The firm highlighted Amgen’s strong product pipeline and steady financial performance, expecting continued momentum in its key drug segments.
- 📈 Daiwa Securities – On February 6, 2025, Daiwa Securities adjusted its price target to $350 from $360, maintaining a positive long-term view on Amgen. Analysts cited expanding market opportunities and the company’s ability to defend its market position despite rising competition.
🔽 Downgrades:
- ⚠️ Bank of America Securities – On February 6, 2025, Bank of America Securities kept its “Sell” rating but raised the price target from $256 to $275. The firm remains cautious about increasing competition in the biotech sector and potential challenges in Amgen’s drug development pipeline, which could weigh on future revenue growth.
- 📉 Citigroup – On January 28, 2025, Citigroup maintained a “Neutral” rating but lowered the price target from $310 to $295. Analysts pointed to uncertainties in revenue growth and market dynamics, suggesting that Amgen may face short-term headwinds despite its strong fundamentals.
These recent ratings reflect a balanced outlook—some analysts see strong potential in Amgen’s product pipeline and financials, while others highlight concerns over competitive pressures and future growth challenges.
Earnings Report Summary
Amgen wrapped up the fourth quarter of 2024 with strong numbers, reporting $9.1 billion in revenue, an 11% jump from the same time last year. The big driver behind this growth? A 14% increase in product sales volume, showing that demand for Amgen’s treatments remains solid across multiple areas.
Looking at the full year, total revenue came in at $33.4 billion, marking a 19% increase compared to 2023. That’s a significant boost, reflecting Amgen’s ability to expand its reach and execute on its strategy.
Several of the company’s top-selling drugs played a big role in these results. Repatha, a medication used to lower cholesterol, saw a 29% jump in sales, hitting $606 million for the quarter. This growth suggests that more patients and healthcare providers are recognizing its benefits for cardiovascular health. Another standout performer was Prolia, Amgen’s osteoporosis treatment, which brought in $1.17 billion, up 13% year over year. Clearly, both drugs are key pillars of the company’s revenue stream.
Beyond its current lineup, Amgen continues to invest heavily in research and development. One of the most exciting prospects is MariTide, an obesity drug candidate that has shown promising results in mid-stage trials. Patients in the study lost up to 20% of their body weight, which is a major breakthrough in obesity treatment. Amgen has big plans for this drug, with Phase 3 trials set to begin in mid-2025. If all goes well, this could become a major revenue driver in the future.
However, not everything has gone smoothly. Another experimental weight-loss drug, AMG 513, hit a regulatory roadblock when the FDA put a hold on its development due to safety concerns. Amgen is working closely with regulators to address the issues, but setbacks like this are a reminder of how challenging drug development can be.
Looking ahead, Amgen is forecasting full-year 2025 earnings per share between $20 and $21.20, with expected revenue in the range of $34.3 billion to $35.7 billion. These numbers reflect steady confidence in its pipeline and current product lineup, despite the challenges ahead.
Overall, Amgen’s latest earnings show that the company is still in growth mode, thanks to strong sales from its leading drugs and promising new treatments on the horizon. There are hurdles, especially with regulatory delays, but Amgen remains a key player in the biotech space with a lot to look forward to.
Financial Health and Stability
Amgen’s financials show a mix of strengths and concerns. The company has incredibly strong margins, with an operating margin of nearly 52%, which is impressive even for the biotech sector. This highlights Amgen’s pricing power and efficiency.
Return on equity (ROE) is another standout figure at 67.55%, but this number is skewed by the company’s high level of debt. While a high ROE is generally a positive sign, in Amgen’s case, it’s partially inflated due to financial leverage.
On the balance sheet, the most notable figure is the company’s total debt, which stands at $60.88 billion. This gives it a sky-high debt-to-equity ratio of over 1,000%, meaning the company has significantly more debt than equity. While Amgen does have $11.97 billion in cash reserves, the overall debt load is something that income investors should monitor.
Despite the high debt, Amgen’s cash flow remains strong, generating $11.49 billion in operating cash flow over the past year. This level of cash flow provides confidence that the company can continue covering its dividend payments, but future dividend growth could be limited unless earnings pick up.
Valuation and Stock Performance
Amgen’s stock is currently trading around $316 per share, with a 52-week range of $253 to $346. The stock has been trending upward in recent months, trading above its 50-day moving average of $283 and close to its 200-day moving average of $306.
From a valuation standpoint, Amgen is trading at a forward P/E ratio of 15.29, which is reasonable for a mature biotech company. The price-to-earnings growth (PEG) ratio of 1.07 suggests that the stock is fairly valued based on expected earnings growth.
Compared to its historical valuation, Amgen isn’t excessively cheap, but it’s also not overvalued. The company’s strong cash flow and defensive nature make it an attractive option for investors looking for stability, particularly in uncertain market conditions.
Risks and Considerations
Industry-Specific Risks
As a biotech company, Amgen faces risks related to drug development, regulatory approval, and competition. The success of its business depends on its ability to bring new drugs to market and maintain exclusivity on existing treatments. Any setbacks in the drug pipeline could impact revenue growth.
Regulatory pressures are another factor. The pharmaceutical industry is constantly under scrutiny, and pricing controls or changes in healthcare policy could impact Amgen’s ability to maintain high margins.
Financial and Dividend Risks
The most pressing financial risk for Amgen is its high level of debt. While the company generates enough cash to cover dividend payments, a prolonged period of weak earnings growth could make dividend increases less likely.
The high payout ratio is another area to watch. If earnings continue to decline, Amgen may need to slow down its dividend growth rate or even pause increases. While a dividend cut isn’t imminent, investors should keep an eye on earnings trends.
Final Thoughts
Amgen is a well-established player in the biotech industry and has been a reliable dividend payer for over a decade. With a solid yield of 3.01% and a history of steady dividend growth, it remains an attractive option for income-focused investors.
However, there are some factors to be mindful of, including its high payout ratio, slowing dividend growth, and significant debt load. While the company’s strong free cash flow provides reassurance, dividend investors should monitor earnings trends and financial stability in the coming quarters.
For investors looking for a defensive stock with a stable dividend, Amgen is a solid choice, but it’s important to keep expectations realistic. The days of rapid dividend growth may be slowing, but as long as the company continues generating strong cash flow, it should remain a reliable source of income for shareholders.
Recent Comments